Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISTINCT targeted thrombosis prophylaxis after total hip or knee arthroplasty
NL-OMON60052Phase 4Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of apixaban in venous thromboembolism (VTE) (5 arms), sponsored by Leiden University Medical Center. Primary endpoints: Symptomatic venous thromboembolism and Major bleeding. Started Oct 2024; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON60052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60052.